Ubs Asset Management Americas Inc Day One Biopharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 116,245 shares of DAWN stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
116,245
Previous 175,416
33.73%
Holding current value
$1.02 Million
Previous $1.14 Million
28.16%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
70.5MCall Options Held
42.8KPut Options Held
60.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$56.6 Million10.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.18MShares$54.4 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.71MShares$41.4 Million0.62% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$39.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.48MShares$30.6 Million0.01% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $646M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...